TheraRadar
← Back
Data updated: Mar 29, 2026

SAPTALIS PHARMS

Infectious DiseaseImmunology
Specialty

SAPTALIS PHARMS is a specialty pharmaceutical company focused on Infectious Disease, Immunology. Key products include LIKMEZ.

1961
Since
7
Drugs
-
Trials
34
Approved (2yr)

Key Drugs

LIKMEZ
metronidazole
7 indications · 2023

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

CYCLOSPORINE 2026-01-21
CYCLOSPORINE 2025-11-28
CLOBETASOL PROPIONATE 2025-11-20
METFORMIN HYDROCHLORIDE 2025-11-10
Manufacturing (CMC)
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE 2025-10-29
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE 2025-09-30
CYCLOSPORINE 2025-09-15
CYCLOSPORINE 2025-08-01
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 50%
1 drugs
Immunology 50%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Infectious Disease, Immunology
Merck big-pharma
Infectious Disease, Immunology
AbbVie big-pharma
Immunology, Infectious Disease
Johnson & Johnson big-pharma
Immunology, Infectious Disease
GSK big-pharma
Infectious Disease, Immunology